Nuclear imaging: A powerful novel approach for tuberculosis

Nuclear Medicine and Biology

Volumn 41, Issue 10, 2014, Pages 777-784

  Johnson, Daniel H ^a   Via, Laura E ^a   Kim, Peter ^a   Laddy, Dominick ^b   Lau, Chuen Yen ^a   Weinstein, Edward A ^c   Jain, Sanjay ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b AERAS   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; PET; Pharmacokinetics; Probe design; SPECT

Indexed keywords

ANTIBIOTIC AGENT; COPPER 64; FLUORODEOXYGLUCOSE F 18; IODINE 125; MATRIX METALLOPROTEINASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM 201;

BACTERIAL STRAIN; BIOMIMETICS; COMPUTER ASSISTED DIAGNOSIS; DISEASE TRANSMISSION; HUMAN; IMMUNE RESPONSE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR PROBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMATE; RADIOLOGICAL PARAMETERS; REGION OF INTEREST; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARD UPTAKE VALUE; TUBERCULOSIS; DIAGNOSTIC IMAGING; ISOLATION AND PURIFICATION; MICROBIOLOGY; NUCLEAR MEDICINE; PROCEDURES;

DIAGNOSTIC IMAGING; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MEDICINE; TUBERCULOSIS;

EID: 84912089866     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.08.005     Document Type: Review

References (108)

1. Hershkovitz I., Donoghue H.D., Minnikin D.E., Besra G.S., Lee O.Y., Gernaey A.M., et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS One 2008, 3(10):e3426.
2. World_Health_Organization Global tuberculosis report 2013 2013, World Health Organization.
3. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
4. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
5. Lin P.L., Flynn J.L. Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
6. Goo J.M., Im J.G., Do K.H., Yeo J.S., Seo J.B., Kim H.Y., et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000, 216:117-121.
7. Robbins S.L., Kumar V. Robbins and Cotran pathologic basis of disease 2010, Saunders/Elsevier, Philadelphia, PA. 8th ed.
8. Drobniewski F.A., Caws M., Gibson A., Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2003, 3:141-147.
9. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000, 161:1376-1395.
10. Ichiyama S., Shimokata K., Takeuchi J. Comparative study of a biphasic culture system (Roche MB Check system) with a conventional egg medium for recovery of mycobacteria. Aichi Mycobacteriosis Research Group. Tuber Lung Dis 1993, 74:338-341.
11. Zar H.J., Connell T.G., Nicol M. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti-Infect Ther 2010, 8:277-288.
12. Jain S.K., Ordonez A., Kinikar A., Gupte N., Thakar M., Mave V., et al. Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int 2013, 2013:7. [783698].
13. Van Dyck P., Vanhoenacker F.M., Van den Brande P., De Schepper A.M. Imaging of pulmonary tuberculosis. Eur Radiol 2003, 13:1771-1785.
14. Khan M.A., Kovnat D.M., Bachus B., Whitcomb M.E., Brody J.S., Snider G.L. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977, 62:31-38.
15. Perlman D.C., el-Sadr W.M., Nelson E.T., Matts J.P., Telzak E.E., Salomon N., et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997, 25:242-246.
16. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
17. Metcalfe J.Z., Everett C.K., Steingart K.R., Cattamanchi A., Huang L., Hopewell P.C., et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 2011, 204(Suppl. 4):S1120-S1129.
18. Lawn S.D., Kerkhoff A.D., Vogt M., Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012, 12:201-209.
19. Chang K., Lu W., Wang J., Zhang K., Jia S., Li F., et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012, 64:580-588.
20. Sohn H., Aero A.D., Menzies D., Behr M., Schwartzman K., Alvarez G.G., et al. Xpert MTB/RIF testing in a low TB incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 2014, 58:970-976.
21. Kayigire X.A., Friedrich S.O., Venter A., Dawson R., Gillespie S.H., Boeree M.J., et al. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol 2013, 51:1894-1898.
22. Eckelman W.C., Lau C.Y., Neumann R.D. Perspective, the one most responsive to change. Nucl Med Biol 2014, 41:297-298.
23. Smith G., Carroll L., Aboagye E.O. New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions. Mol Imaging Biol 2012, 14:653-666.
24. Lau C.-Y., Maldarelli F., Eckelman W.C., Neumann R.D. Rational development of radiopharmaceuticals for HIV-1. Nucl Med Biol 2014, 41:299-308.
25. Heyn C., Bowen C.V., Rutt B.K., Foster P.J. Detection threshold of single SPIO-labeled cells with FIESTA. Magn Reson Med 2005, 53:312-320.
26. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000, 41:661-681.
27. Eckelman W.C., Reba R.C., Gibson R.E., Rzeszotarski W.J., Vieras F., Mazaitis J.K., et al. Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med 1979, 20:350-357.
28. Boswell C.A., Tesar D.B., Mukhyala K., Theil F.P., Fielder P.J., Khawli L.A. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010, 21:2153-2163.
29. Hilderbrand S.A., Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol 2010, 14:71-79.
30. Lee S., Xie J., Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010, 49:1364-1376.
31. Pysz M.A., Gambhir S.S., Willmann J.K. Molecular imaging: current status and emerging strategies. Clin Radiol 2010, 65:500-516.
32. Skotland T. Molecular imaging: challenges of bringing imaging of intracellular targets into common clinical use. Contrast Media Mol Imaging 2012, 7:1-6.
33. North R.J., Izzo A.A. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J Exp Med 1993, 177:1723-1733.
34. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003, 47:833-836.
35. Wayne L.G., Sohaskey C.D. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 2001, 55:139-163.
36. Choyke P., Kurdziel K.A., Mena E., Lindenberg M.L. Meeting the challenges of PET-based molecular imaging in cancer. Expert Rev Mol Diagn 2013, 13:671-680.
37. Bell G.I., Burant C.F., Takeda J., Gould G.W. Structure and function of mammalian facilitative sugar transporters. J Biol Chem 1993, 268:19161-19164.
38. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998, 25:317-322.
39. Zhuang H., Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002, 32:47-59.
40. Bettegowda C., Foss C.A., Cheong I., Wang Y., Diaz L., Agrawal N., et al. Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A 2005, 102:1145-1150.
41. Diaz L.A., Foss C.A., Thornton K., Nimmagadda S., Endres C.J., Uzuner O., et al. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One 2007, 2(10):e1007.
42. Davis S.L., Be N.A., Lamichhane G., Nimmagadda S., Pomper M.G., Bishai W.R., et al. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 2009, 4(7):e6297.
43. Backus K.M., Boshoff H.I., Barry C.S., Boutureira O., Patel M.K., D'Hooge F., et al. Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nat Chem Biol 2011, 7:228-235.
44. D'Souza M.M., Sharma R., Jaimini A., Panwar P., Bansal A., Tripathi M., et al. Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT. Nucl Med Commun 2012, 33:408-414.
45. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
46. Tomasi G., Kenny L., Mauri F., Turkheimer F., Aboagye E.O. Quantification of receptor-ligand binding with [(1)(8)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging 2011, 38:2186-2197.
47. Feng F., Zhang H., Zhu Z., Li C., Shi Y., Zhang Z. The application of anti-ESAT-6 monoclonal antibody fluorescent probe in ex vivo near-infrared fluorescence imaging in mice with pulmonary tuberculosis. Luminescence 2013, 10.1002/bio.2593.
48. Gemmel F., Dumarey N., Welling M. Future diagnostic agents. Semin Nucl Med 2009, 39:11-26.
49. Vinjamuri S., Hall A.V., Solanki K.K., Bomanji J., Siraj Q., O'Shaughnessy E., et al. Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996, 347:233-235.
50. Palestro C., Love C., Caprioli R., Marwin S., Richardson H., Haight J., et al. Phase II study of 99mTc-ciprofloxacin uptake in patients with high suspicion of osteomyelitis. J Nucl Med 2006, 47(1):152P.
51. Misra U.K., Kalita J., Das B.K. Single photon emission computed tomography in tuberculous meningitis. Postgrad Med J 2000, 76:642-645.
52. Sathekge M.M., Maes A., Pottel H., Stoltz A., van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 2010, 100:598-601.
53. Eckelman W.C. Preface for "The quantification with FDG as seen by a physician" by Galli et al. Nucl Med Biol 2013, 40:719.
54. Ohno Y., Takenaka D., Kanda T., Yoshikawa T., Matsumoto S., Sugihara N., et al. Adaptive iterative dose reduction using 3D processing for reduced- and low-dose pulmonary CT: comparison with standard-dose CT for image noise reduction and radiological findings. AJR Am J Roentgenol 2012, 199:W477-W485.
55. Makris N.E., Huisman M.C., Kinahan P.E., Lammertsma A.A., Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging 2013, 40:1507-1515.
56. Keyes J.W. SUV: standard uptake or silly useless value?. J Nucl Med 1995, 36:1836-1839.
57. Owen D.R., Yeo A.J., Gunn R.N., Song K., Wadsworth G., Lewis A., et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012, 32:1-5.
58. Razak H.R., Geso M., Abdul Rahim N., Nordin A.J. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT. J Med Imaging Radiat Oncol 2011, 55:556-562.
59. Treglia G., Taralli S., Calcagni M.L., Maggi F., Giordano A., Bonomo L. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. J Comput Assist Tomogr 2011, 35:387-393.
60. Yu Y.H., Hsu W.H., Hsu N.Y., Lin T.Y., Hsia T.C., Sun S.S., et al. The use of dual phase 201Tl SPECT for differentiating pulmonary malignancies from benign lesions. Jpn J Clin Oncol 2004, 34:445-451.
61. Kim I.J., Lee J.S., Kim S.J., Kim Y.K., Jeong Y.J., Jun S., et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 2008, 35:808-814.
62. Macdonald K., Searle J., Lyburn I. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin Radiol 2011, 66:244-250.
63. Kandula P., Shirazi P. Localization of Tc-99m sestamibi and TI-201 in an unsuspected calcified intrathoracic mass. Clin Nucl Med 1995, 20:1000-1002.
64. Schuurmans M.M., Ellmann A., Bouma H., Diacon A.H., Dyckmans K., Bolliger C.T. Solitary pulmonary nodule evaluation with 99mTc-methoxy isobutyl isonitrile in a tuberculosis-endemic area. Eur Respir J 2007, 30:1090-1095.
65. Stefanescu C., Rusu V., Boisteanu D., Azoicai D., Costin M., Oleniuc D., et al. 99mTc isonitrils biophysical aspects in pulmonary tuberculosis. Part I. In vivo evaluation of 99mTc MIBI and 99mTc Tetrofosmin biophysical localization mechanisms. Rev Med Chir Soc Med Nat Iasi 2006, 110:944-949.
66. Alavi A., Gupta N., Alberini J.L., Hickeson M., Adam L.E., Bhargava P., et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002, 32:293-321.
67. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992, 33:1972-1980.
68. Park I.N., Ryu J.S., Shim T.S. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 2008, 33:1-3.
69. Demura Y., Tsuchida T., Uesaka D., Umeda Y., Morikawa M., Ameshima S., et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009, 36:632-639.
70. Lin P.L., Coleman T., Carney J.P., Lopresti B.J., Tomko J., Fillmore D., et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013, 57:4237-4244.
71. Via L.E., Schimel D., Weiner D.M., Dartois V., Dayao E., Cai Y., et al. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 2012, 56:4391-4402.
72. Via L.E., Weiner D.M., Schimel D., Lin P.L., Dayao E., Tankersley S.L., et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 2013, 81(8):2909-2919.
73. Bagci U., Foster B., Miller-Jaster K., Luna B., Dey B., Bishai W.R., et al. A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res 2013, 3:55.
74. Davis S.L., Nuermberger E.L., Um P.K., Vidal C., Jedynak B., Pomper M.G., et al. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009, 53:4879-4884.
75. Martinez V., Castilla-Lievre M.A., Guillet-Caruba C., Grenier G., Fior R., Desarnaud S., et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis 2012, 16:1180-1185.
76. Mehta S. Patterns of systemic uptake of 18-FDG with positron emission tomography/computed tomography (PET/CT) studies in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm 2012, 20:434-437.
77. Sathekge M., Maes A., Kgomo M., Stoltz A., Van de Wiele C. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 2011, 52:880-885.
78. Su M., Fan Q., Fan C., Tian Y., Li F., Yang X., et al. Lung sequestration and Pott disease masquerading as primary lung cancer with bone metastases on FDG PET/CT. Clin Nucl Med 2009, 34:236-238.
79. Basu S. 18F-FDG PET/CT as a sensitive and early treatment monitoring tool: will this become the major thrust for its clinical application in infectious and inflammatory disorders?. J Nucl Med 2012, 53:165. [author reply -6].
80. Liao C.Y., Chen J.H., Liang J.A., Yeh J.J., Kao C.H. Meta-analysis study of lymph node staging by 18F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions. Eur J Radiol 2012, 81:3518-3523.
81. Sathekge M., Maes A., D'Asseler Y., Vorster M., Van de Wiele C. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nucl Med Commun 2012, 33:581-590.
82. Foss C.A., Harper J.S., Wang H., Pomper M.G., Jain S.K. Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis 2013, 208:2067-2074.
83. Harper J., Skerry C., Davis S.L., Tasneen R., Weir M., Kramnik I., et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012, 205:595-602.
84. Tasneen R., Jain S.K., Nuremberger E. Cavitary TB in C3HeB/FeJ mice. Novel therapeutic approaches to tuberculosis. Keystone, CO: Keystone Symposia Conference 2014.
85. Ordonez A.A., Pokkali S., Mease R., Klunk M., Foss C.A., Pomper M.G., et al. Characterization of iodo-DPA-713 imaging in mice receiving novel TB treatments. Novel therapeutic approaches to tuberculosis. Keystone, CO: Keystone Symposia Conference 2014.
86. Belton M., Elkington P., Fryer T., Nijran K., Friedland J.S. Hypoxia increases matrix metalloproteinase-driven immunopathology during tuberculosis infection: evidence from in vitro studies and patients with active pulmonary disease. Host Response in Tuberculosis: Keystone Symposia. Whistler, British Columbia, Canada 2013.
87. Kong Y., Yao H., Ren H., Subbian S., Cirillo S.L., Sacchettini J.C., et al. Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci U S A 2010, 107:12239-12244.
88. Zhang T., Li S.Y., Nuermberger E.L. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One 2012, 7(1):e29774.
89. Andreu N., Zelmer A., Sampson S.L., Ikeh M., Bancroft G.J., Schaible U.E., et al. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. J Antimicrob Chemother 2013, 68:2118-2127.
90. Bass J.B., Farer L.S., Hopewell P.C., O'Brien R., Jacobs R.F., Ruben F., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994, 149:1359-1374.
91. Jenne J.W., Beggs W.H. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin. Am Rev Respir Dis 1973, 107:1013-1021.
92. Muller M., dela Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004, 48:1441-1453.
93. Langer O., Muller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 2004, 5:463-481.
94. Pasipanodya J.G., Srivastava S., Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012, 55:169-177.
95. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(Suppl. 2):ii25-ii31.
96. Prideaux B., Dartois V., Staab D., Weiner D.M., Goh A., Via L.E., et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 2011, 83:2112-2118.
97. Hooker J.M. Modular strategies for PET imaging agents. Curr Opin Chem Biol 2010, 14:105-111.
98. Fischman A.J., Alpert N.M., Babich J.W., Rubin R.H. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 1997, 29:923-956.
99. Liu L., Xu Y., Shea C., Fowler J.S., Hooker J.M., Tonge P.J. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 2010, 53:2882-2891.
100. Weinstein E.A., Liu L., Ordonez A.A., Wang H., Hooker J.M., Tonge P.J., et al. Noninvasive determination of 2-[18F]-fluoroisonicotinicacid hydrazide pharmacokinetics by positron emission tomography in mycobacterium tuberculosis infected mice. Antimicrob Agents Chemother 2012, 56:6284-6290.
101. Zar H.J., Hanslo D., Apolles P., Swingler G., Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005, 365:130-134.
102. Fox W., Ellard G.A., Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3:S231-S279.
103. Via L.E., Lin P.L., Ray S.M., Carrillo J., Allen S.S., Eum S.Y., et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008, 76:2333-2340.
104. Pan H., Yan B.S., Rojas M., Shebzukhov Y.V., Zhou H., Kobzik L., et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005, 434:767-772.
105. Driver E.R., Ryan G.J., Hoff D.R., Irwin S.M., Basaraba R.J., Kramnik I., et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012, 56:3181-3195.
106. Capuano S.V., Croix D.A., Pawar S., Zinovik A., Myers A., Lin P.L., et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003, 71:5831-5844.
107. Matthews P.M., Rabiner E.A., Passchier J., Gunn R.N. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 2012, 73:175-186.
108. FDA Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies 2006, Food and Drug Administration.